May 16, 2022 Synthetic Biologics Reports First Quarter 2022 Operational Highlights and Financial Results
May 10, 2022 Synthetic Biologics Reports Positive Safety Data on SYN-020 Intestinal Alkaline Phosphatase Phase 1 Multiple Ascending Dose Clinical Trial
May 9, 2022 Synthetic Biologics to Host Conference Call and Webcast to Discuss First Quarter 2022 Operational Highlights and Financial Results
May 5, 2022 Synthetic Biologics Announces Formation of Scientific Advisory Board to Advance Oncology Pipeline
May 4, 2022 Synthetic Biologics Announces Presentation on VCN-11, a Novel Oncolytic Adenovirus Designed to Evade Neutralizing Antibodies at the Upcoming 25th Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
March 28, 2022 Synthetic Biologics Announces Journal for ImmunoTherapy of Cancer Publication of Phase 1 Trial of Intravenous VCN-01 Oncolytic Adenovirus in Patients With Advanced Solid Tumors
March 23, 2022 Synthetic Biologics Announces Management Transitions in Support of Strategic Transformation
March 16, 2022 Synthetic Biologics Reports 2021 Year End Operational Highlights and Financial Results
